<- Go Home

Vyant Bio, Inc.

Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company’s central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson’s disease (PD). The company is based in Cherry Hill, New Jersey.

Market Cap

$1.2M

Volume

153.2K

Cash and Equivalents

$2.8M

EBITDA

-$13.3M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

-$339.0K

Profit Margin

85.39%

52 Week High

$1.58

52 Week Low

$0.14

Dividend

N/A

Price / Book Value

0.27

Price / Earnings

-0.09

Price / Tangible Book Value

0.27

Enterprise Value

-$861.2K

Enterprise Value / EBITDA

0.07

Operating Income

-$13.7M

Return on Equity

122.41%

Return on Assets

-51.76

Cash and Short Term Investments

$2.8M

Debt

$708.0K

Equity

$4.5M

Revenue

$397.0K

Unlevered FCF

-$9.4M

Sector

Biotechnology

Category

N/A

Hedge Funds that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Yellowbrick Portfolios that own this stock

PREMIUM

Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).

Upgrade to Yellowbrick Premium

Company Stock Pitches